Telix Pharmaceuticals is experiencing a re-acceleration in revenue growth, reaching 16.6% in 2026Q2, as its radiopharmaceutical portfolio gains commercial traction. However, this top-line momentum is being fully consumed by rapidly scaling R&D ($179.3M) and SG...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | $0.11+140.3% vs $0.04 | $477M-0.5% vs $480M |
Q1 2026 Feb 19, 2026 | -$0.01-135.4% vs $0.03 | $413M-1.2% vs $418M |
Q3 2025 Aug 20, 2025 | -$0.01-105.1% vs $0.13 | $390M-0.0% vs $390M |
Q1 2025 Feb 20, 2025 | $0.11+22.5% vs $0.09 | $267M+97.9% vs $135M |
Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript
Telix Pharmaceuticals Limited (TLX) M&A Call Transcript
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.
Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.
Benchmark TLX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Telix Pharmaceuticals Limited (TLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.72 | $3.63B | -488.53 | 53.91% | -0.89% | -1.8% | — | |
| $57.94 | $14.56B | 20.84 | 6.98% | 35.33% | 42.49% | — | |
| $6.83 | $2.48B | 22.03 | 43.31% | 8.11% | 7.77% | — | |
| $8.33 | $346.88M | -2450.00 | 10.37% | 69.76% | — | — | |
| $99.65 | $6.49B | 29.22 | 0.5% | 17.69% | 23.27% | — | |
| $141.05 | $268.1B | 19.62 | 5.97% | 22.93% | 29.64% | — |
Telix Pharmaceuticals Limited (TLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Telix Pharmaceuticals Limited (TLX) stock FAQ — growth, dividends, profitability & financials explained
Telix Pharmaceuticals Limited (TLX) reported $2.50B in revenue for fiscal year 2025.
Telix Pharmaceuticals Limited (TLX) grew revenue by 53.9% over the past year. This is strong growth.
Yes, Telix Pharmaceuticals Limited (TLX) is profitable, generating $83.0M in net income for fiscal year 2025 (-0.9% net margin).
Telix Pharmaceuticals Limited (TLX) has a return on equity (ROE) of -1.8%. Negative ROE indicates the company is unprofitable.
Telix Pharmaceuticals Limited (TLX) had negative free cash flow of $75.6M in fiscal year 2025, likely due to heavy capital investments.
